• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Updates from EUCAST AFST, October 2025

The following ECOFFs and breakpoints for antifungal agents have been established or revised and are now found in the associated revised rationale documents, the breakpoint document and the ECOFF and breakpoints document available at the EUCAST website: Download PDF

Get to know more

Guidance Documents

Guidance Documents All Antibiotic Infection Methodology Pathogen Regulatory Document Title Date of Publication Previous Versions and Notes Infective endocarditis - EUCAST guidance on the reporting of antimicrobial susceptibility testing results July 2025 December 2024 Daptomycin in endocarditis and…

Get to know more

EUCAST news January 2021

There is only little news from EUCAST January 2021. The next EUCAST Steering Committee meeting is on February 1 - 3. Again via video links. Several users of EUCAST breakpoint tables have asked how to translate dosages (Tab Dosage) based on adult administration to pediatric clinical situations -…

Get to know more

EUCAST breakpoints offer two levels of susceptible (S and I).

In 2019, EUCAST abandoned the previously used definitions of S, I and R, and introduced categories S (Susceptible, standard dose), I (Susceptible, increased exposure) and R (Resistant). All breakpoints, dosages and modes of administration were reviewed and revised to match the changed definitions.…

Get to know more

Public consultations

Public consultation Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Previous public consultations with comments and EUCAST responses 2025 Archive Proposed new breakpoints for…

Get to know more

Breakpoints and methods for C. diphtheriae and C. ulcerans available

The breakpoint table v 13.0 (2023) is under preparation (release for consultation 5 December, 2022). As part of this table, there are specific breakpoints for Corynebacterium diphtheriae and C. ulcerans. EUCAST has been requested to make these available as soon as possible. The now published table…

Get to know more

Fluoroquinolone breakpoints under review

Fluroquinolone breakpoints are under review and will likely be lowered for Enterobacterales whereas breakpoints for other species are less likely to change. Laboratories and manufacturers of susceptibility testing devices are adviced to take this under consideration and to be prepared to cope with…

Get to know more

Several public consultations - deadline 15 November 2021

There are several public consultations which will expire 15 November, 2021. Vibrio species - genral consultationon EUCAST clinical breakpoints for five species pathogenic to man(1 October - 15 November). Queries on the material can be addressed to G Kahlmeter (gunnar.kahlmeter@eucast.org)…

Get to know more

When there are no antifungal breakpoints

When there are no antifungal breakpoints? 16 April 2024 first published on 16 April 2024, errata published 30 Sep, 2024: “dashes (“-“) are replaced by R, C. dubliniensis has been deleted as BPs have been set, and the species (dermatis) specified in table 2.” Download PDF EUCAST guidance on…

Get to know more

Consultation on clinical breakpoints for anaerobic bacteria - additional agents.

EUCAST has so far included five species/species groups in the breakpoint table for anaerobic bacteria; Bacteroides, Prevotella spp, Fusobacterium necrophorum, Clostridium perfringens and Cutibacterium acnes . This general consultation concerns additional agents (aminopenicillins, carbapenems, and…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here